Insights

Acquired Digital Therapy Amblyotech was acquired by Novartis in 2020, signaling strong validation and potential for larger scale digital-therapy collaborations. Opportunities for partners or suppliers could include integration with Novartis or leveraging their distribution channels in ophthalmology and digital health.

Niche Ophthalmology Focus Specializes in amblyopia and ocular diseases with electronic media therapies, presenting a targeted opportunity for eyecare networks, pediatric clinics, vision therapy providers, and pharmaceutical players seeking digital treatment adjuncts in ophthalmology.

Startup Scale Gap Small team size and revenue under one million indicate potential needs for scalable tech, commercialization support, strategic partnerships, and professional services to accelerate product deployment, regulatory navigation, and go-to-market efforts.

Digital Therapy Footprint Experience with video-based therapies and consumer-facing digital platforms (Weebly, WordPress, video players) suggests opportunities to upsell platform modernization, data analytics, patient engagement tools, and enterprise-grade hosting or security services.

Cross-Industry Synergy Past collaborations with game-like interventions (Dig Rush) and a background in digital health echo potential for partnerships with gaming, education, or pediatric healthcare distributors to broaden adoption and co-development of engaging amblyopia therapies.

Similar companies to Amblyotech

Amblyotech Tech Stack

Amblyotech uses 8 technology products and services including Weebly, WordPress, Google Fonts API, and more. Explore Amblyotech's tech stack below.

  • Content Management System
  • Content Management System
  • Google Fonts API
    Font Scripts
  • Mustache
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • Video.js
    Javascript Libraries
  • Quantcast
    System Analytics & Monitoring
  • Google Analytics
    Web Analytics

Amblyotech's Email Address Formats

Amblyotech uses at least 1 email format:
Amblyotech Email FormatsExamplePercentage
Last@amblyotech.comDoe@amblyotech.com
100%

Frequently Asked Questions

What is Amblyotech's official website and social media links?

Minus sign iconPlus sign icon
Amblyotech's official website is amblyotech.com and has social profiles on LinkedIn.

How much revenue does Amblyotech generate?

Minus sign iconPlus sign icon
As of August 2026, Amblyotech's annual revenue is estimated to be <$1M.

What is Amblyotech's SIC code and NAICS code?

Minus sign iconPlus sign icon
Amblyotech's SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Amblyotech have currently?

Minus sign iconPlus sign icon
As of August 2026, Amblyotech has approximately 2 employees across 1 continents, including North America. Key team members include : J. K. Explore Amblyotech's employee directory with LeadIQ.

What industry does Amblyotech belong to?

Minus sign iconPlus sign icon
Amblyotech operates in the Biotechnology industry.

What technology does Amblyotech use?

Minus sign iconPlus sign icon
Amblyotech's tech stack includes Weebly, WordPress, Google Fonts API, Mustache, jQuery, Video.js, Quantcast and Google Analytics.

What is Amblyotech's email format?

Minus sign iconPlus sign icon
Amblyotech's email format typically follows the pattern of Last@amblyotech.com. Find more Amblyotech email formats with LeadIQ.

How much funding has Amblyotech raised to date?

Minus sign iconPlus sign icon
As of August 2026, Amblyotech has raised $602K in funding. The last funding round occurred on Jan 24, 2018.
Amblyotech logo

Amblyotech

Biotechnology2-10 Employees

Amblyotech is a small biotechnology research company based in Phoenix, Arizona, that develops electronic media therapies for amblyopia and other ocular conditions in both children and adults. Its products are digital treatments designed to be used by patients to deliver therapy through interactive media, including game-based approaches intended to stimulate visual processing in each eye. The work sits at the intersection of vision science and digital therapeutics, seeking non-invasive options to improve binocular vision.

The company's target market comprises patients with amblyopia and related ocular conditions who may benefit from non-invasive digital therapies. A notable development occurred in April 2020 when Novartis Pharmaceuticals Corporation acquired Amblyotech. Previously, in 2018, Amblyotech released Dig Rush, a game-based therapeutic concept developed with Ubisoft for children with amblyopia.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $602K

    Amblyotech has raised a total of $602K of funding over 2 rounds. Their latest funding round was raised on Jan 24, 2018 as a Seed.

  • <$1M

    Amblyotech's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.